171 related articles for article (PubMed ID: 17018900)
1. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.
Vootukuru V; Liew YP; Nally JV
Med Oncol; 2006; 23(3):419-22. PubMed ID: 17018900
[TBL] [Abstract][Full Text] [Related]
2. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.
Stavroulopoulos A; Nakopoulou L; Xydakis AM; Aresti V; Nikolakopoulou A; Klouvas G
Ren Fail; 2010; 32(8):1000-4. PubMed ID: 20722569
[TBL] [Abstract][Full Text] [Related]
3. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.
Kim HO; Lee SY; Shim JJ; Kang KH; Shin BK
J Thorac Oncol; 2010 Mar; 5(3):401-2. PubMed ID: 20186027
[No Abstract] [Full Text] [Related]
4. [Pemetrexed nephrotoxicity].
Izzedine H
Bull Cancer; 2015 Feb; 102(2):190-7. PubMed ID: 25641712
[TBL] [Abstract][Full Text] [Related]
5. Kidney tubular toxicity of maintenance pemetrexed therapy.
Glezerman IG; Pietanza MC; Miller V; Seshan SV
Am J Kidney Dis; 2011 Nov; 58(5):817-20. PubMed ID: 21849225
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed induced aseptic meningitis.
Shah BK; O'Keefe S
Acta Oncol; 2012 Mar; 51(3):399-400. PubMed ID: 21936754
[No Abstract] [Full Text] [Related]
7. Pemetrexed-induced hyperpigmentation of the skin.
Schallier D; Decoster L; de Greve J
Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-induced lung toxicity: a case report.
Breuer S; Nechushtan H
Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
[No Abstract] [Full Text] [Related]
9. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
10. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
11. Combined renal tubular acidosis and diabetes insipidus in hematological disease.
Hoorn EJ; Zietse R
Nat Clin Pract Nephrol; 2007 Mar; 3(3):171-5. PubMed ID: 17322929
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function].
Funaguchi N; Nakajima Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Asano M; Iihara H; Mori H; Ohno Y; Minatoguchi S
Gan To Kagaku Ryoho; 2015 Jun; 42(6):705-8. PubMed ID: 26199241
[TBL] [Abstract][Full Text] [Related]
13. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function].
Kono M; Sakata Y; Sugawara T; Abe K; Miyamori S; Miura S; Hata Y; Funaki M; Inata J; Kanehara M; Hiraki K; Iwamoto Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2587-90. PubMed ID: 25596053
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed-induced typhlitis in non-small cell lung cancer.
Shvartsbeyn M; Edelman MJ
J Thorac Oncol; 2008 Oct; 3(10):1188-90. PubMed ID: 18827618
[TBL] [Abstract][Full Text] [Related]
17. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Izzedine H; Escudier B; Rouvier P; Gueutin V; Varga A; Bahleda R; Soria JC
Ann Oncol; 2013 Sep; 24(9):2421-5. PubMed ID: 23798615
[TBL] [Abstract][Full Text] [Related]
18. Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.
Sun X; Sheng L; Deng Q; Liu P; Lu K
Pharmacology; 2011; 88(5-6):242-4. PubMed ID: 21997597
[TBL] [Abstract][Full Text] [Related]
19. Immune hemolytic anemia after treatment with pemetrexed for lung cancer.
Park GM; Han KS; Chang YH; Kim CH; Lee JC
J Thorac Oncol; 2008 Feb; 3(2):196-7. PubMed ID: 18303446
[No Abstract] [Full Text] [Related]
20. Pemetrexed-Induced Nephrogenic Diabetes Insipidus.
Fung E; Anand S; Bhalla V
Am J Kidney Dis; 2016 Oct; 68(4):628-632. PubMed ID: 27241854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
